Ticker League

Regeneron Pharmaceuticals (REGN) Profit Bridge

See what drove Regeneron Pharmaceuticals's net income from TTM through Q1 2025 to TTM through Q1 2026 — every line ranked by dollar impact, from revenue gains to taxes.

Revenue YoY

+5.92%

Operating Income YoY

-5.27%

Net Income YoY

-1.70%

Net Margin Δ

-234 bps

Net income bridge for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Net income: −$75.90M-1.70%

Profit bridge breakdown for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Net Income$4.50B
  • Revenue$833.90M
  • Cost of Revenue−$304.80M
  • Operating Expenses−$731.00M
  • Other Income / Expense$374.60M
  • Income Tax−$248.60M
  • Net Income$4.42B
Identity check: drivers reconcile to ΔNI within $0.00
Want the full P&L structure?Income Statement Waterfall

Frequently asked questions

Data & methodology